| Cardiome Pharma and its co-development partner Astellas Pharma announced that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID, or vernakalant hydrochloride, Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm. The ACT 5 trial, previously announced in August 2009, is expected to be completed in the first half of 2011. :theflyonthewall.com |
